Tuesday, July 1, 2025 7/1/2025

Utilizing IgG Autoantibodies as Biomarkers in IgA Nephropathy

Award Number: R43DK126526
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2020
PERIOD OF PERFORMANCE END DATE: 06/30/2021

Group Awards By:

View Award Description

Utilizing IgG Autoantibodies as Biomarkers in IgA Nephropathy - Abstract IgA nephropathy (IgAN) is the most common primary glomerulonephritis and an important cause of kidney failure. It is a mesangioproliferative glomerular disease defined by characteristic IgA1 mesangial deposits. These mesangial deposits likely originate from circulating immune complexes that contain IgA1 with Galactose (Gal)-deficient O-glycans (Gd-IgA1) that are bound by IgG autoantibodies. The pathogenesis model describing IgAN as an autoimmune disease was based on the discovery of IgG autoantibodies that bind Gd-IgA1 in the laboratory of Dr. Jan Novak at the University of Alabama at Birmingham (UAB). As part of these studies, Dr. Novak's laboratory developed assays for the detection and quantitative assessment of both Gd-IgA1 and IgG autoantibodies. The use of these assays for analysis of serum samples from several cohorts of IgAN patients has been published; both the Gd-IgA1 assay and the IgG autoantibody assay have potential as markers for preclinical detection of IgAN, prediction of outcome, and monitoring the response to therapy. The established pathogenesis model of IgAN enabled pharmaceutical industry to start developing and testing treatment for the disease. However, only secondary markers (e.g., proteinuria and estimated glomerular filtration rate [eGFR]) are currently used as the endpoints, adding to the time and cost of clinical trials. Thus, clinical-grade tests that assess primary causative markers are urgently needed. To address this requisite, we have licensed the intellectual property from UAB that surrounds the IgAN assays developed in Dr. Novak's laboratory. The goal of this proposal is to characterize and validate the components of the IgG autoantibody assay and establish standard operating procedures (SOPs) so that it can be validated and commercialized for clinical use.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2020	RELIANT GLYCOSCIENCES LLC	1716 WINGFIELD CIR	BIRMINGHAM	AL	35242	SHELBY	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	12/28/2021	NEW	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $211,707 )
2020	2020	RELIANT GLYCOSCIENCES LLC	1716 WINGFIELD CIR	BIRMINGHAM	AL	35242	SHELBY	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	6/19/2020	NEW	$211,707
														Subtotal = $211,707

Grand Total All Awards = $211,707

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Utilizing IgG Autoantibodies as Biomarkers in IgA Nephropathy

Award Number: R43DK126526

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2020

PERIOD OF PERFORMANCE END DATE: 06/30/2021

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer